22. (New) A method for inhibiting growth of tumor cells in a tumor-bearing animal comprising administering to said mammal an amount of a compound of claim 1 for a time and under conditions effective to sufficiently inhibit ras farnesyl transferase to prevent, inhibit or diminish the growth rate of said tumor cells.

23. (New) A method of inhibiting smooth muscle proliferation in a mammal which has been subjected to injury of vascular tissue comprising administering to said mammal an amount of a compound of claim 1 for a time and under conditions effective to sufficiently inhibit ras farnesyl transferase to inhibit said smooth muscle proliferation.

24. (New) A composition comprising a compound according to claim 1, and a carrier.

25. (New) A composition comprising a suitable carrier and a compound according to claim 1 in an amount effective to sufficiently inhibit ras farnesyl transferase for use as a pharmaceutical.

REMARKS

The Examiner has requested a sequence listing for the amino acid sequences that are noted on page 52 as part of an assay procedure. This short peptide is not found as any part of the claims and is mentioned solely in order to provide the details of the assay described. Applicants wish to point out that the divisional application, Serial No. 09/331,876, now issued US Pat. No. 6,265,382, contained the same specification and included the same peptide sequence. This patent was issued on July 24, 2001 without the need for providing a sequence listing. For these reasons, Applicants respectfully submit that a sequence listing is not necessary in this case and request that this requirement be reconsidered and withdrawn.

The Examiner has provisionally rejected Claim 1 for obviousness-type double patenting. As the Examiner has noted, there are not yet allowable conflicting claims. Therefore, Applicants request that this rejection be withdrawn until such time as there is a

real issue of possible conflicting claims to be addressed. Since the claims of this case are not yet allowed, one can not compare the breadth or scope to the claims of US 6,265,382.

The Examiner has rejected all of the claims (1-8, 11-14, and 19) under 35 U.S.C. § 112, first paragraph, as containing subject matter not described in the specification in such a way as to enable one skilled in the art to make and /or use the invention. Applicants respectfully traverse this rejection and request reconsideration. It is well established that enablement under 35 U.S.C. § 112 requires that the specification teaches how to make and use the claimed invention without undue experimentation. However, a working example of every permutation of the invention is not required. Nor is it necessary to disclose what is well known to those skilled in the art.

Applicants respectfully submit that the entire subject matter of claim 1 is described in the specification sufficiently to enabled one skilled in the art to make and use the claimed subject matter. The compounds claimed in claim 1 are described and several methods of making such compound are exemplified. In addition, the specification teaches how to assay the inhibitory activity of the compounds. The specification teaches pharmaceutically acceptable salts of the compositions are those "within the scope of sound medical judgement, suitable for use in contact with patients without undue [side effects] . . .". (page 13, lines 25-28) The specification also teaches dosage forms, dosages and routes of administration. One of ordinary skill in the art would know after reading the specification that such compound are useful as pharmaceutical compositions and how to use them as such without undue experimentation. The Examiner has recognized this fact by stating that the following claims are enabled:

> *A method for inhibiting ras farnesyl transferase in a mammal in need thereof comprising administering to said mammal a compound of claim 1 for a time and under conditions effective to inhibit ras farnesyl transferase.*
>
> *A method for inhibiting ras farnesyl transferase in a mammal affected with restenosis, cancer or psoriasis comprising administering to said mammal a compound of claim 1 for a time and under conditions effective to inhibit ras farnesyl transferase.*

(Office Action page 3, lines 15-20).

A method for inhibiting growth of tumor cells in a tumor-bearing animal comprising administering to said mammal a compound of claim 1 for a time and under conditions effective to inhibit ras farnesyl transferase.

A method of inhibiting smooth muscle proliferation in a mammal which has been subjected to injury of vascular tissue comprising administering to said mammal a compound of claim 1 for a time and under conditions effective to inhibit C

(Office Action page 3, line 22-page 4, line 6).

It is also well accepted that *in vitro* data is sufficiently predictive of the *in vivo* activity of compounds that, absent sufficient grounds for doubting the inventors assertions, the claims can not be rejected simply because *in vivo* data has not been provided in the specification. The applicants have provided sufficient nexus between the inhibition of ras farnesyl transferase and the treatment of restenosis, cancer and psoriasis in the specification. Please see pages 2, line 10 – page 3, line 4, and page 3 line 26 – page 5, line 5. Applicants assert that there is sufficient nexus provided between the inhibition of ras farnesyl transferase and treatment of the cited conditions and have also taught the subject matter of the pending claims with sufficient clarity to enable one of skill in the art to practice the claimed invention.

Applicants respectfully request reconsideration and withdrawal of the rejections in light of the amendments and remarks made herein. Since the claims are now in condition for allowance, applicants respectfully request early notice to that effect.

Applicants respectfully request that the period for response be extended three months to and including November 18, 2001. Please charge the three-month extension fee (large entity), and any additional fees or credits, to Deposit Account number 23-0455.

Finally, the undersigned notes that subsequent correspondence should be addressed to:

Rosanne Goodman
Pfizer Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
(734-622-4182).

Respectfully submitted,

Date: 11/19/01

Rosanne Goodman
Reg. No. 52,534
Patent Department
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel: (734-622-4182)
Fax: (734-622-1553)
Fax: (973) 385-3117